论文部分内容阅读
目的探讨浸润性乳腺癌中c-erbB-2阳性表达对临床治疗及预后判断的意义。方法收集2010年1月~2011年12月本院手术浸润性乳腺癌病例172例,统计其TMN分期、肿瘤直径及淋巴结转移情况,c-erbB-2情况。结果 172例患者中116例患者c-erbB-2呈阳性,阳性患者中101例有淋巴转移,Ⅰ期15例,ⅡA 61例,ⅡB 40例。6例因肺转移死亡,17例骨转移。结论 c-erbB-2是浸润性乳腺癌一个独立的预后因素,其阳性患者淋巴转移和远处转移早,应着重全身性综合治疗以提高生存率。
Objective To investigate the significance of c-erbB-2 positive expression in clinical treatment and prognosis in invasive breast cancer. Methods 172 patients with invasive breast cancer were collected from January 2010 to December 2011 in our hospital. The TMN stage, tumor diameter, lymph node metastasis and c-erbB-2 were analyzed. Results Of the 172 patients, 116 were positive for c-erbB-2, 101 were positive for lymph node metastases, 15 were in stage I, 61 in stage IIA, and 40 in stage IIB. Six died of lung metastases and 17 had bone metastases. Conclusion c-erbB-2 is an independent prognostic factor for invasive breast cancer. Positive lymph node metastasis and distant metastasis of early positive patients should focus on systemic treatment to improve the survival rate.